stem-cell-congress-cardiology-2018-posters

Biomedical Research

Volume 29

Page 58

allied

academies

CARDIOLOGY AND CARDIOVASCULAR MEDICINE

STEM CELLS AND REGENERATIVE MEDICINE

International Conference on

J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

STAGE SPECIFIC DIFFERENTIATION OF WHARTON JELLY DERIVED

MESENCHYMAL STEM CELLS TO GENERATE HIGH QUALITY

NEURONS

Zaffar Equbal

National Institute of Immunology, India

eurodegenerative disorders of the central nervous system (CNS) remain as one of the major health concern, accounting

for more than 10% of deaths due to different diseases. In neurodegenerative disorders, Alzheimer’s disease, Parkinson’s

disease (PD), Amyotrophic lateral sclerosis (ALS), Multiple system atrophy (MSA) and Huntington disease are the major

contributors. The current therapy, which involves medication and deep brain stimulation at advance stage, focuses on

symptomatic treatment with none of them being able to counteract the progression of the disease. Keeping in mind the

limitations associated with the present treatments, study of cell based therapy has been initiated. In this study we have

successfully trans-differentiated Wharton Jelly derived mesenchymal Stem cells (WJ-MSCs) into neuronal fate. WJ-MSCs

were chosen for the study because of their hypoimmunogenic, immunomodulatory, and non-tumorigenic property. WJ-

MSCs upon treatment with FGF-2 and EGF acquired neuroectodermal fate. Further analysis of these cells confirmed drastic

decrease in the expression of MSCs related genes with concomitant expressing of SOX1, the important transcription factor

involved in neural fate determination. Moreover, there was a drastic reduction in the number of cells expressing CD73 and

CD105, pan-markers of MSCs. These neuroectodermal cells where further induced and differentiated into mature neuronal

cells.

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006